{{Drugbox
| IUPAC_name = L-Serine, L-α-aspartyl-L-seryl-L-tryptophyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-valylL-isoleucyl-L-lysyl-L-leucyl-L-cysteinylglycyl-L-arginyl-L-α-glutamyl-L-leucyl-L-valyl-L- arginyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-cysteinylglycyl-L- methionyl-L-seryl-L-threonyl-L-tryptophyl-, cyclic (11→11'),(23→24')-bis(disulfide) with 5-oxo-L-prolyl-L-leucyl-L-tyrosyl-L-seryl-L-alanyl-L-leucyl-L-alanyl-L-asparaginyl-L-lysyl-L- cysteinyl-L-cysteinyl-L-histidyl-L-valylglycyl-L-cysteinyl-L-threonyl-L-lysyl-L-arginyl-L- seryl-L-leucyl-L-alanyl-L-arginyl-L-phenylalanyl-L-cysteine cyclic (10'→15')-disulfide
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category = N/A
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_status = Investigational
| routes_of_administration = [[Intravenous]]
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = none
<!-- Identifiers -->
| ATC_prefix = C01
| ATC_suffix = DX21
| CAS_number = 99489-94-8
| KEGG = D10488
<!-- Chemical data -->
| C=256 | H=408 | N=74 | O=74 | S=8
| molecular_weight = 5963 g/mol 
}}

'''Serelaxin''' ('''RLX030''') is an investigational drug for the treatment of acute [[heart failure]] (AHF), targeting the [[relaxin receptor]]. Serelaxin is a recombinant form of human [[relaxin]]-2, a hormone that (among other functions) is produced during pregnancy and mediates the haemodynamic changes that occur during this time,<ref name="Spreitzer" /><ref name="aerztezeitung" /> such as increased blood output of the heart and blood flow in the kidney.<ref name="pmid21613576" />  Human-relaxin-2 mediates vasodilation (widening of blood vessels) by increasing the production of [[nitric oxide]] (NO), a potent [[vasodilator]].<ref name="Tousoulis" />  Activation of the relaxin receptor [[RXFP1]] activates several enzymes in a [[phosphorylation cascade]] that eventually results in the activation of NO synthase in endothelial cells and the subsequent production of NO.<ref name="Bathgate" />  Relaxin can also bind to a secondary receptor, endothelial B receptor,{{Clarify|date=March 2014}} which is upregulated as a result of the previous pathway.<ref name="Miyares" />  Relaxin binding to endothelial B receptor on endothelial cells also induces vasodilation.<ref name="Teichman1" />

Relaxin causes vasodilation by an indirect mechanism, where it inhibits the potent vasoconstrictors angiotensin II and endothelin.<ref name="Teichman2" />  
In addition to vasodilation, the effects of relaxin are also seen in the kidneys, by significantly increasing [[creatinine]] clearance,<ref name="Ponikowski" /> which is a measure of kidney function, as well as increased renal blood flow.<ref name="Teichman1" />
Relaxin also functions as a cardiac stimulant.<ref name="Bathgate" />  Studies have demonstrated that relaxin increases calcium sensitivity of cardiac [[myofilament]]s as well as increasing phosphorylation of the myofilaments by [[protein kinase C]] (PKC).<ref name="Shaw" />  These modifications both function to increase the force generated by the myofilaments without increasing the energy consumption of the cardiac myocytes.<ref name="Shaw" />  Thus relaxin and serelaxin can increase [[stroke volume]], the amount of blood pumped per heart beat, without increasing the energy demand on the already strained heart of acute heart failure patients.

==Acute heart failure==
Serelaxin has undergone clinical trials in patients with acute heart failure,<ref name="Teerlink" /> conducted by [[Novartis]].  Serelaxin has completed several clinical trials as a therapy for AHF.  Phase I trials examined safety and tolerability,<ref name="Du" /> while phase II trials evaluated its haemodynamic effects and symptom relief.  The Pre-RELAX-AHF phase II trial administered a dose of 30&nbsp;µg/kg/day and showed a decrease in blood pressure, improved [[dyspnoea]], and increased renal blood flow.<ref name="Teichman1" />  In phase III the RELAX-AHF trial gave a 48hr intravenous infusion of the same dose.<ref name="King" />  It significantly improved patients' dyspnoea, resulted in a 30% reduction in worsening of heart failure symptoms, a decreased hospital stay and a reduction in signs and symptoms of congestion.<ref name="Teerlink" /><ref name="Filippatos" />  The FDA granted serelaxin "breakthrough therapy" designation, meant to expedite the development and review of drugs for life-threatening conditions.<ref name="Novartis" /> On 22 March 2017, Novartis announced that the global Phase III study of serelaxin in patients with acute heart failure did not meet its primary endpoints.<ref>https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart</ref>

== References ==
{{reflist|35em|refs=
<ref name="Teerlink">{{cite journal|last1=Teerlink|first1=John R|last2=Cotter|first2=Gad|last3=Davison|first3=Beth A|last4=Felker|first4=G Michael|last5=Filippatos|first5=Gerasimos|last6=Greenberg|first6=Barry H|last7=Ponikowski|first7=Piotr|last8=Unemori|first8=Elaine|last9=Voors|first9=Adriaan A|last10=Adams|first10=Kirkwood F|last11=Dorobantu|first11=Maria I|last12=Grinfeld|first12=Liliana R|last13=Jondeau|first13=Guillaume|last14=Marmor|first14=Alon|last15=Masip|first15=Josep|last16=Pang|first16=Peter S|last17=Werdan|first17=Karl|last18=Teichman|first18=Sam L|last19=Trapani|first19=Angelo|last20=Bush|first20=Christopher A|last21=Saini|first21=Rajnish|last22=Schumacher|first22=Christoph|last23=Severin|first23=Thomas M|last24=Metra|first24=Marco|displayauthors=6|title=Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial|journal=The Lancet|volume=381|issue=9860|year=2013|pages=29–39|issn=0140-6736|doi=10.1016/S0140-6736(12)61855-8|pmid=23141816}}</ref><ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 4 March 2013| title = Neue Wirkstoffe – Serelaxin| journal = Österreichische Apothekerzeitung| issue = 5/2013| page = 36| language = German}}</ref>
<ref name=Tousoulis>{{cite journal|last=Tousoulis|first=D|author2=Kampoli, A. |author3=Papageorgiou, C. |author4=Stefanadis, C. |title=The role of nitric oxide on endothelial function|journal=Curr Vasc Pharmacol|year=2012|volume=10|pages=4–18}}</ref> 
<ref name="aerztezeitung">{{cite web|url=http://www.aerztezeitung.de/medizin/krankheiten/herzkreislauf/herzinsuffizienz/article/826906/fortschritt-sicht-schwangerschaftshormon-herzschwaeche.html?sh=1&h=-655181939|journal=ÄrzteZeitung|date=23 November 2012|title=Schwangerschaftshormon gegen Herzschwäche|trans_title=Pregnancy hormone against heart failure|author=Dirk Einecke}}</ref>
<ref name="pmid21613576">{{cite journal | author = Conrad KP | title = Maternal vasodilation in pregnancy: the emerging role of relaxin | journal = Am. J. Physiol. Regul. Integr. Comp. Physiol. | volume = 301 | issue = 2 | pages = R267–75 |date=August 2011 | pmid = 21613576 | pmc = 3154715 | doi = 10.1152/ajpregu.00156.2011 }}</ref>
<ref name="Bathgate">{{cite journal|last1=Bathgate|first1=R. A. D.|last2=Halls|first2=M. L.|last3=van der Westhuizen|first3=E. T.|last4=Callander|first4=G. E.|last5=Kocan|first5=M.|last6=Summers|first6=R. J.|title=Relaxin Family Peptides and Their Receptors|journal=Physiological Reviews|volume=93|issue=1|year=2013|pages=405–480|issn=0031-9333|doi=10.1152/physrev.00001.2012}}</ref><ref name="Miyares">{{cite journal|last=Miyares|first=M|author2=Davis, K. |title=Serelaxin, a breakthrough investigational intravenous agent for acute heart failure|journal=P.T|year=2013|volume=38|pages=606–611}}</ref> 
<ref name="Teichman1">{{cite journal|last=Teichman|first=S|author2=Unemori, E. |author3=Teerlink, J. |author4=Cotter, G. |author5=Metra, M. |title=Relaxin, review of biology and potential role in treating heart failure|journal=Curr Heart Fail Rep|year=2010|volume=75|pages=75–82}}</ref> 
<ref name="Teichman2">{{cite journal|last=Teichman|first=S|author2=Unemori, E. |author3=Dschietzig, T. |author4=Conrad, K. |author5=Voors, A.|title=Relaxin, a pleiotropic vasodilator for the treatment of heart failure|journal=Heart Fail Rev|year=2009|volume=14|pages=321–329 |doi=10.1007/s10741-008-9129-3|display-authors=etal}}</ref> 
<ref name="Ponikowski">{{cite journal|last=Ponikowski|first=P.|author2=Mitroic, V. |author3=Rude, M. |author4=Fernandez, A. |author5=Voors, A.|title=A randomized, double-blind, placebo controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure|journal=Eur Heart J|year=2014|volume=35|pages=431–441 |doi=10.1093/eurheartj/eht459|display-authors=etal}}</ref> 
<ref name="Shaw">{{cite journal|last=Shaw|first=E.|author2=Wood, P. |author3=Kulpa, J. |author4=Yang, F. |author5=Summerlee, A.|title=Relaxin alters cardiac myofilament function through a PKC-dependent pathway|journal=Am J Physiol Heart Circ Physiol|year=2009|volume=297|pages=29–36|display-authors=etal}}</ref> 
<ref name="Du">{{cite journal|last=Du|first=X.|author2=Hewitson, T. |author3=Nguyen, M. |author4=Samuel, C. |title=Therapeutic effects of Serelaxin in acute heart failure|journal=Circ J|year=2014|volume=12|pages=6–19}}</ref> 
<ref name="King">{{cite journal|last=King|first=A|title=Heart failure-promising data for Serelaxin|journal=Nat Rev Cardiol|year=2013|volume=10|page=3|doi=10.1038/nrcardio.2012.174}}</ref> 
<ref name="Filippatos">{{cite journal|last=Filippatos|first=G.|author2=Teerlink, J. |author3=Farmakis, D. |author4=Cotter, G. |author5=Davison, B.|title=Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial|journal=Eur Heart|year=2014|volume=89|pages=90–103|display-authors=etal}}</ref> 
<ref name="Novartis">{{cite web|last=Novartis Global|title=FDA grants breakthrough designation to Novartis' serelaxin (RLX030) for acute heart failure|url=http://www.novartis.com/newsroom/media-releases/en/2013/1711047.shtml|publisher=Novartis Global}}</ref>
}}

{{Vasodilators used in cardiac diseases}}
{{Protein and peptide receptor modulators}}

[[Category:Novartis]]
[[Category:Drugs acting on the cardiovascular system]]